These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 7921691)
1. [Surveillance of secondary effects of vaccination]. Duclos P Sante; 1994; 4(3):215-20. PubMed ID: 7921691 [TBL] [Abstract][Full Text] [Related]
2. [Postmarketing surveillance of secondary effects of vaccines]. Duclos P Rev Epidemiol Sante Publique; 1994; 42(5):425-33. PubMed ID: 7973002 [TBL] [Abstract][Full Text] [Related]
3. Vaccinovigilance in Europe--need for timeliness, standardization and resources. Lankinen KS; Pastila S; Kilpi T; Nohynek H; Mäkelä PH; Olin P Bull World Health Organ; 2004 Nov; 82(11):828-35. PubMed ID: 15640918 [TBL] [Abstract][Full Text] [Related]
4. Elective termination of pregnancy after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS): 1990-2006. Chang S; Ball R; Braun MM Vaccine; 2008 May; 26(19):2428-32. PubMed ID: 18406499 [TBL] [Abstract][Full Text] [Related]
5. [Adverse events after vaccination]. Nøkleby H; Bergsaker MA Tidsskr Nor Laegeforen; 2006 Oct; 126(19):2541-4. PubMed ID: 17028637 [TBL] [Abstract][Full Text] [Related]
6. [Surveillance system for adverse events following immunization against yellow fever in Burkina Faso in 2008. Good practice recommendations]. Yaméogo TM; Breugelmans JG; Kambou JL; Badolo O; Tiendrebéogo S; Traoré E; Avokey F; Yactayo S Med Trop (Mars); 2009 Aug; 69(4):320-1. PubMed ID: 19725376 [TBL] [Abstract][Full Text] [Related]
7. Monitoring and assessing vaccine safety: a European perspective. Lopalco PL; Johansen K; Ciancio B; De Carvalho Gomes H; Kramarz P; Giesecke J Expert Rev Vaccines; 2010 Apr; 9(4):371-80. PubMed ID: 20370548 [TBL] [Abstract][Full Text] [Related]
8. Death and serious illness following influenza vaccination: a multidisciplinary investigation. Rue-Cover A; Iskander J; Lyn S; Burwen DR; Gargiullo P; Shadomy S; Blostein J; Bridges CB; Haber P; Satzger RD; Ball R; Seward JF Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):504-11. PubMed ID: 19373848 [TBL] [Abstract][Full Text] [Related]
10. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511 [TBL] [Abstract][Full Text] [Related]
11. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network. LaRussa PS; Edwards KM; Dekker CL; Klein NP; Halsey NA; Marchant C; Baxter R; Engler RJ; Kissner J; Slade BA Pediatrics; 2011 May; 127 Suppl 1():S65-73. PubMed ID: 21502239 [TBL] [Abstract][Full Text] [Related]
12. Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007. Niu MT; Ball R; Woo EJ; Burwen DR; Knippen M; Braun MM; Vaccine; 2009 Jan; 27(2):290-7. PubMed ID: 18992783 [TBL] [Abstract][Full Text] [Related]
13. Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002. Begier EM; Burwen DR; Haber P; Ball R; Clin Infect Dis; 2004 Mar; 38(6):771-9. PubMed ID: 14999618 [TBL] [Abstract][Full Text] [Related]
14. Association between health care providers' influence on parents who have concerns about vaccine safety and vaccination coverage. Smith PJ; Kennedy AM; Wooten K; Gust DA; Pickering LK Pediatrics; 2006 Nov; 118(5):e1287-92. PubMed ID: 17079529 [TBL] [Abstract][Full Text] [Related]
15. Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Sever JL; Brenner AI; Gale AD; Lyle JM; Moulton LH; West DJ; Pharmacoepidemiol Drug Saf; 2002; 11(3):189-202. PubMed ID: 12051118 [TBL] [Abstract][Full Text] [Related]
16. Safety monitoring in vaccine development and immunization. Lee CJ; Lee LH; Lu CH; Huang YJ; Chu ML Acta Paediatr Taiwan; 2006; 47(1):7-13. PubMed ID: 17016963 [TBL] [Abstract][Full Text] [Related]
17. Developing a national system for dealing with adverse events following immunization. Mehta U; Milstien JB; Duclos P; Folb PI Bull World Health Organ; 2000; 78(2):170-7. PubMed ID: 10743281 [TBL] [Abstract][Full Text] [Related]
18. Surveillance of adverse events following immunization: 10 years' experience in Oman. Al Awaidy S; Bawikar S; Prakash KR; Al Rawahi B; Mohammed AJ East Mediterr Health J; 2010 May; 16(5):474-80. PubMed ID: 20799545 [TBL] [Abstract][Full Text] [Related]
19. Ensuring the optimal safety of licensed vaccines: a perspective of the vaccine research, development, and manufacturing companies. Kanesa-thasan N; Shaw A; Stoddard JJ; Vernon TM Pediatrics; 2011 May; 127 Suppl 1():S16-22. PubMed ID: 21502248 [TBL] [Abstract][Full Text] [Related]